Clinical Trial Update: A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer [Phase 1]

View source ↗

Summary

Nuvectis Pharma's NXP800 is being studied in a Phase 1 trial for advanced solid tumors with expansion into ovarian cancer, and the study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Clear Cell Carcinoma
• Ovarian Endometrioid Carcinoma

Drugs mentioned

• NXP800 (NXP800)

Snippet

Sponsor: Nuvectis Pharma, Inc. | Conditions: Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING